knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 21:37:08 - browse：24413

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Gain of function research would be limited under House proposal

hotspot

Wikipedia

WSS

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

UnitedHealth’s board chair also owns a personal investment firm

Poor hospice wound care hurts patients and families

Does good food count as health care? Study aims to find out

Childhood cancer progress stalls for Black, Hispanic kids: Report

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

hotspot

knowledge

focus

Psychedelics group wrestles with new pharma identity

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Duchenne breakthrough therapy leaves behind pioneering families

HHS leader on health, climate change and biopharma emissions

In age of alternative facts, a scholarly course on calling out crap

The explosion of genetic testing requires a new approach

As demand for Covid shots wanes, Moderna seeks its next success

A daunting task: navigating dual Medicare, Medicaid eligibility

Drug repurposing or repositioning? The language matters

Ransomware attacks on hospitals: Study outlines patient impact

focus

Astellas still sees hope in its gene therapy after four deaths

Congress must reauthorize a committee to support older Americans

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Anthos stroke drug appears safer than common blood thinner

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

hotspot

hotspot

Wikipedia

explore